Spyre Therapeutics Statistics
Share Statistics
Spyre Therapeutics has 58.71M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 58.71M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 81.49K |
| FTD / Avg. Volume | 13.9% |
Short Selling Information
The latest short interest is 8.25M, so 14.05% of the outstanding shares have been sold short.
| Short Interest | 8.25M |
| Short % of Shares Out | 14.05% |
| Short % of Float | 16.95% |
| Short Ratio (days to cover) | 21.97 |
Valuation Ratios
The PE ratio is -0.44 and the forward PE ratio is -8.64.
| PE Ratio | -0.44 |
| Forward PE | -8.64 |
| PS Ratio | 167.52 |
| Forward PS | 330 |
| PB Ratio | 0.81 |
| P/FCF Ratio | -1.49 |
| PEG Ratio | n/a |
Enterprise Valuation
Spyre Therapeutics Inc. has an Enterprise Value (EV) of 44.09M.
| EV / Earnings | -0.13 |
| EV / Sales | 49.76 |
| EV / EBITDA | -0.34 |
| EV / EBIT | -0.18 |
| EV / FCF | -0.44 |
Financial Position
The company has a current ratio of 10.68, with a Debt / Equity ratio of 0.
| Current Ratio | 10.68 |
| Quick Ratio | 10.68 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.84% and return on capital (ROIC) is -90.21%.
| Return on Equity (ROE) | -1.84% |
| Return on Assets (ROA) | -0.99% |
| Return on Capital (ROIC) | -90.21% |
| Revenue Per Employee | 29.53K |
| Profits Per Employee | -11.29M |
| Employee Count | 30 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -26.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 55.42% in the last 52 weeks. The beta is 2.91, so Spyre Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.91 |
| 52-Week Price Change | 55.42% |
| 50-Day Moving Average | 30.74 |
| 200-Day Moving Average | 31.56 |
| Relative Strength Index (RSI) | 31.4 |
| Average Volume (20 Days) | 586.17K |
Income Statement
In the last 12 months, Spyre Therapeutics had revenue of $886.00K and earned -$338.79M in profits. Earnings per share was $-49.12.
| Revenue | 886.00K |
| Gross Profit | -78.00K |
| Operating Income | -242.30M |
| Net Income | -338.79M |
| EBITDA | -127.82M |
| EBIT | -242.30M |
| Earnings Per Share (EPS) | -49.12 |
Balance Sheet
The company has $188.89M in cash and $84.56M in debt, giving a net cash position of $104.34M.
| Cash & Cash Equivalents | 188.89M |
| Total Debt | 84.56M |
| Net Cash | 104.34M |
| Retained Earnings | -764.41M |
| Total Assets | 421.09M |
| Working Capital | 363.54M |
Cash Flow
In the last 12 months, operating cash flow was -$99.91M and capital expenditures $0, giving a free cash flow of -$99.91M.
| Operating Cash Flow | -99.91M |
| Capital Expenditures | 0 |
| Free Cash Flow | -99.91M |
| FCF Per Share | -14.49 |
Margins
Gross margin is -8.8%, with operating and profit margins of -27.35K% and -38.24K%.
| Gross Margin | -8.8% |
| Operating Margin | -27.35K% |
| Pretax Margin | -38.24K% |
| Profit Margin | -38.24K% |
| EBITDA Margin | -14.43K% |
| EBIT Margin | -27.35K% |
| FCF Margin | -11.28K% |
Dividends & Yields
SYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -203.9% |
| FCF Yield | -7.06% |
Analyst Forecast
The average price target for SYRE is $49.5, which is 105.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $49.5 |
| Price Target Difference | 105.5% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Sep 8, 2023. It was a backward split with a ratio of 1:25.
| Last Split Date | Sep 8, 2023 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | 6.4 |
| Piotroski F-Score | 3 |